Join IAG at the International Conference on Alzheimer’s and Parkinson’s Diseases
IAG’s bio partnering team will be attending the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD 2023, meeting in Gothenburg, Sweden on March 28-April 1, 2023.
IAG’s team will be meeting with key biotech companies and addressing the challenges biotech companies face in neurology trials to explore IAG’s novel strategies to include advanced imaging biomarkers.
IAG partners with biotechnology and pharmaceutical companies and apply AI and Precision Medicine to accelerate drug approval.
IAG takes a holistic approach to biotech’s clinical development and brings together:
- An efficient purpose-built cloud-based system with embedded quality controls for trial data management (DYNAMIKA)
- Patented methodologies for quantitative assessment of treatment efficacy and safety
- Expertise to ensure regulatory compliance, targeted drug development and scientific credibility of your data
- Ensures that its bio-pharmaceutical clients gain the most benefits of early objective decision making on their treatment efficacy from utilizing advanced imaging techniques in their trials
Discover our risk assessment and management strategies to overcome the challenges in your neurology trial by contacting IAG at firstname.lastname@example.org
About the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2023 )
The AD/PD™ Conference offers a high-quality scientific program covering the most recent research, clinical trials, developments, and treatments in Alzheimer’s and Parkinson’s, with emphasis on overlaps and congruent results among AD. This provides participants with unparalleled and powerful insights into distinct neurodegenerative diseases in one setting to examine their similarities and differences.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: email@example.com
Follow the Company: Linkedin